English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background and Objective: Acute vasoreactivity testing using inhaled nitric oxide (NO) is performed to determine the treatment strategy in patients with pulmonary hypertension. Operators of the test are exposed to NO and nitrogen dioxide (NO2) to the same extent during the test procedure, but the safety zone for operators in the catheterization laboratory is unclear. This study aimed to clarify the safety zone for operators during the NO inhalation test. Methods: The mask was placed on the examination table in the catheterization laboratory. NO was added using the INOvent® (INO-Therapeutics, LLC), which was attached to an oxygen line and delivered NO to the mask. During simulated NO inhalation tests (n = 10) in a catheterization laboratory, NO and NO2 concentrations were measured at nine speci ed locations: at the mask out ow port (E0); 25 cm (E25) and 50 cm (E50) from the mask out ow port; heights of 25 cm (A25) and 50 cm (A50) above E0 and E25; and a height of 25 cm (B25) below E0 and E25. During NO inhalation testing conducted in 5 patients, concentrations of NO and NO2 were measured at E0 and E25A50. The Steel-Dwass and Student t-tests were used to perform intergroup analyses. Results: NO-E0A25 (0.00 ± 0.00 ppm), NO-E25A25 (0.01 ± 0.10 ppm), NO-E0A50 (0.00 ± 0.00 ppm), and NO-E25A50 (0.00 ± 0.00 ppm) were signi cantly lower than NO-E0 (17.01 ± 0.22 ppm), NO-E25 (4.06 ± 0.47 ppm), and NO-E50 (1.90 ± 0.39 ppm) (p < 0.01, all comparisons). NO2 concentrations were less than 0.1 ppm at all nine locations. NO and NO2 concentrations were not affected by room temperature (20, 24, or 28°C) or the ow rate of oxygen (15 or 10 L/min). During NO inhalation testing in patients, NOE25A50 (0.20 ± 0.45 ppm) was signi cantly lower than NO-E0 (7.20 ± 2.39 ppm, p < 0.01); however, no signi cant difference in the NO2 concentration was seen between NO2-E0 (0.220 ± 0.179 ppm) and NO2-E25A50 (0.180 ± 0.205 ppm). Conclusions: An operator safety zone in NO vasoreactivity testing is a zone >25 cm in all directions from the mask for NO inhalation. The concentrations of NO and NO2 to which an operator is exposed in the clinical setting are within the permissible exposure limits de ned by the National Institute for Occupational Safety and Health.

Operator Safety Zone During the Nitric Oxide Inhalation Vasoreactivity Test for Pulmonary Hypertension Patients